Physician profile
Colin Ligon
NPI 1316180540
$15,769.77
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $590 · 2021: $2,593 · 2022: $6,331 · 2023: $6,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,250 · Food and Beverage: $1,933 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,250.00 |
| Food and Beverage | $1,932.81 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,398.60 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,277.15 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $1,440.44 | 2020-2023 | Acthar |
| Amgen INC. | $1,316.89 | 2020-2023 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $964.32 | 2020-2023 | |
| Janssen Biotech, INC. | $634.24 | 2020-2023 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $506.44 | 2021-2023 | Saphnelo |
| Lilly USA, LLC | $465.92 | 2020-2023 | Taltz |
| Glaxosmithkline, LLC. | $400.40 | 2020-2022 | |
| Horizon Therapeutics Plc | $393.37 | 2020-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $352.67 | 2022-2023 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $295.23 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $245.63 | 2021-2023 | Strensiq |
| Aurinia Pharma U.S., INC. | $191.02 | 2021-2023 | Lupkynis |
| Genentech USA, INC. | $127.05 | 2022-2023 | Actemra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $122.60 | 2022-2023 | |
| Genzyme Corporation | $98.84 | 2021-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $68.77 | 2022-2023 | Arcalyst |
| Pharming Healthcare, INC. | $54.46 | 2022-2023 | Ruconest |
| Organon LLC | $54.00 | 2023 | Renflexis |
| Ucb, INC. | $49.40 | 2023 | Cimzia |
| Daiichi Sankyo INC. | $45.64 | 2021 | |
| Bio Products Laboratory USA, INC. | $35.62 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $32.82 | 2021-2023 | Uptravi, Opsumit |
| Mylan Institutional INC. | $31.29 | 2023 | Hulio |
| Radius Health, INC. | $31.22 | 2022 | |
| Fresenius Kabi USA, LLC | $27.69 | 2023 | Idacio |
| Oxford Immunotec USA INC | $27.63 | 2021 | |
| Sobi, INC | $23.49 | 2022 | |
| Kyowa Kirin, INC. | $21.09 | 2022 | |
| Sandoz INC. | $18.81 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $17.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Ligon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.